2020-06-03T09:21:22Z
2020-06-03T09:21:22Z
2017-04-11
2020-06-03T09:21:23Z
INTRODUCTION: The recent dramatic increase in the incidence of antimicrobial resistance has been recognized by organizations such as the United Nations and World Health Organization as well as the governments of the USA and several European countries. A relatively new weapon in the fight against severe infections caused by multi-drug resistant bacteria is antimicrobial peptides (AMPs). These include colistin, currently regarded as the last line of antimicrobial therapy against multi-drug resistant microorganisms. Areas covered: Here, the authors provide an overview of the current research on AMPs. The focus is AMPs currently being developed for the treatment of recalcitrant bacterial infections, the synergies of AMPs and antibiotics, and the activity of AMPs against biofilm. This review also includes a brief introduction into the use of AMPs in infections caused by Mycobacterium, fungi, and parasites. Expert opinion: In research into new antimicrobials, AMPs are gaining increasing attention. While many are natural and are produced by a wide variety of organisms, others are being newly designed and chemically synthesized in the laboratory to achieve novel antimicrobial agents. The same strategy to fight infections in nature is thus being effectively exploited to safeguard human and animal health.
Article
Accepted version
English
Antibiòtics; Pèptids; Resistència als medicaments; Espectrometria de masses; Antibiotics; Peptides; Drug resistance; Mass spectrometry
Taylor and Francis
Versió postprint del document publicat a: https://doi.org/10.1080/14712598.2017.1315402
Expert Opinion On Biological Therapy, 2017, vol. 17, num. 6, p. 663-676
https://doi.org/10.1080/14712598.2017.1315402
(c) Taylor and Francis, 2017